New, long-acting drugs may hold hope for millions of people who often suffer migraines.Studies of two of these medicines, given as shots every month or so, found they cut the frequency of the ...

Astellas Pharma will partner with Frequency Therapeutics to develop Frequency’s lead candidate—the Phase IIa-bound sensorineural hearing loss regenerative therapeutic FX-322—through a collaboration ...

Arcadia Healthcare Solutions recently released a new tool allowing users to examine a drug’s changes in frequency of prescriptions and price over the last five years. The resource contains information ...

An experimental regenerative therapy that Frequency Therapeutics was developing to treat a form of hearing loss has failed to beat a placebo in a clinical trial for the second time in two years, ...

For people with tough-to-treat epilepsy, seizures can be both frightening and dangerous, but a new experimental pill may bring significant relief to over one-third of them. Dubbed XEN1101, the new ...

New, long-acting drugs may hold hope for millions of people who often suffer migraines. Studies of two of these medicines, given as shots every month or so, found they cut the frequency of the ...

New, long-acting drugs may hold hope for millions of people who often suffer migraines. Studies of two of these medicines, given as shots every month or so, found they cut the frequency of the ...